The genetic testing company 23andMe $ME, which filed for bankruptcy earlier this year, has informed the U.S. bankruptcy court of its intention to reopen the auction process for the sale of its assets, including its extensive repository of customer genetic data. This move follows a new bid of $305 million from 23andMe’s co-founder, Anne Wojcicki, surpassing the previous leading offer of $256 million from pharmaceutical giant Regeneron Pharmaceuticals $REGN. The initial auction was expected to conclude in May, but this fresh proposal could reshape the company’s financial and operational future.